HCA Healthcare (HCA)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$405.00-1.03%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
Warn: Primary pillar under pressure — Achieve 2026 revenue near $77.25 billion: FY26 revenue guidance $77.0B-$79.5B vs $77.25B target.
HCA Healthcare grows revenue about 5% yearly, aiming for $77.25 billion in 2026. It keeps buying back shares with a $10 billion program and pays rising dividends, now $0.78 per share. The company manages capital spending around $5.25 billion. These actions support steady profit and cash flow.
Revenue growth could slow if volumes drop or costs rise. Management changes and volatile capital allocation may hurt execution. The recent selloff shows market doubts about sustaining growth and margins.
The market prices HCA about 50% below our fair value near $840, reflecting cautious views despite 5% revenue growth expected. Our fair value is well above the Street median, showing a valuation gap we see as justified but risky.
Breaks if: Buybacks cease or fall materially below program pace
Breaks if: Capex exceeds $5.5B or falls below $5.0B materially
Dividend falls below $0.78 per share quarterly
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
HCA represents a durable compounder in the healthcare sector. The current thesis state is intact, supported by strong recent financial performance, though management execution has shown volatility.
The market currently prices HCA as cheap compared to its peers, with a notable expectations gap. This suggests that investors may not be fully factoring in the company's recent strong performance and its ability to maintain guidance.
Fundamentals are likely to remain stable, given the company's strong recent financial performance. However, management's mixed execution on guidance reaffirmation and capital expenditures could introduce some uncertainty in the near term.
The thesis hinges on management's ability to reaffirm guidance in the upcoming earnings call and the performance of sector bellwethers. Additionally, macroeconomic factors, such as employment trends, could impact HCA's performance.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. HCA's acquisition of 40 urgent care clinics strengthens its market presence. However, a guidance cut and increased uninsured patients threaten revenue growth expectations.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue falls below $76.5B in FY26
Maintain and deliver on 2026 revenue guidance range of $76.5B to $80B with stable operating environment and volume growth assumptions.
Overall, HCA appears well-positioned for the next few years, but key management decisions and external economic conditions will play a critical role. Not investment advice.